NasdaqGM - Delayed Quote • USD
BioAtla, Inc. (BCAB)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 7:12 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.44 | -0.38 | -1.61 | -1.48 |
| Low Estimate | -0.51 | -0.48 | -1.79 | -1.74 |
| High Estimate | -0.35 | -0.33 | -1.5 | -1.03 |
| Year Ago EPS | -0.75 | -0.7 | -2.58 | -1.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.64 | -0.8 | -0.79 | -0.54 |
| EPS Actual | -0.75 | -0.7 | -0.56 | -0.48 |
| Difference | -0.11 | 0.1 | 0.23 | 0.06 |
| Surprise % | -17.20% | 12.50% | 29.10% | 11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.44 | -0.38 | -1.61 | -1.48 |
| 7 Days Ago | -0.44 | -0.38 | -1.61 | -1.48 |
| 30 Days Ago | -0.5 | -0.46 | -1.93 | -1.76 |
| 60 Days Ago | -0.5 | -0.46 | -1.93 | -1.76 |
| 90 Days Ago | -0.64 | -0.65 | -2.55 | -2.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 5 | 5 | 5 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BCAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 41.30% | -- | -- | 9.10% |
| Next Qtr. | 45.70% | -- | -- | 11.50% |
| Current Year | 37.60% | -- | -- | 5.70% |
| Next Year | 8.10% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JMP Securities: Market Outperform to Market Outperform | 5/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/28/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 12/5/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/8/2023 |
Related Tickers
CNTX Context Therapeutics Inc.
1.7100
-2.29%
VINC Vincerx Pharma, Inc.
0.7120
-1.26%
CGEM Cullinan Therapeutics, Inc.
22.40
-0.62%
ALXO ALX Oncology Holdings Inc.
9.01
-2.91%
CTMX CytomX Therapeutics, Inc.
1.6400
-1.80%
VOR Vor Biopharma Inc.
1.2250
-3.16%
SNSE Sensei Biotherapeutics, Inc.
0.6503
-1.84%
ENTA Enanta Pharmaceuticals, Inc.
12.91
+2.95%
ITOS iTeos Therapeutics, Inc.
16.70
-0.60%
GBIO Generation Bio Co.
3.2600
-1.81%